Scarica l'app Stockscreener
58.22
3.91%
-2.37
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$60.59
Aprire:
$60.02
Volume 24 ore:
17.86M
Relative Volume:
1.43
Capitalizzazione di mercato:
$118.87B
Reddito:
$48.48B
Utile/perdita netta:
$7.27B
Rapporto P/E:
16.33
EPS:
3.5648
Flusso di cassa netto:
$12.85B
1 W Prestazione:
-0.83%
1M Prestazione:
-5.69%
6M Prestazione:
+26.37%
1 anno Prestazione:
+17.36%
Intervallo 1D:
$58.03
$60.09
Intervallo di 1 settimana:
$57.28
$60.78
Portata 52W:
$42.52
$62.89
Bristol Myers Squibb Co Stock (BMY) Company Profile
Nome
Bristol Myers Squibb Co
Settore
Industria
Telefono
(609) 252-4621
Indirizzo
ROUTE 206 AND PROVINCE LINE ROAD, PRINCETON, NY
Compare BMY vs LLY, JNJ, ABBV, AZN, NVS
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
BMY
Bristol Myers Squibb Co
|
58.22 | 118.87B | 48.48B | 7.27B | 12.85B | 3.5648 |
LLY
Lilly Eli Co
|
963.33 | 862.01B | 72.25B | 25.28B | 5.96B | 27.78 |
JNJ
Johnson Johnson
|
227.19 | 546.90B | 96.36B | 21.04B | 17.80B | 8.6488 |
ABBV
Abbvie Inc
|
206.60 | 365.43B | 62.82B | 3.62B | 17.82B | 2.0331 |
AZN
Astrazeneca Plc
|
184.74 | 286.50B | 60.48B | 10.40B | 8.05B | 3.3297 |
NVS
Novartis Ag Adr
|
146.57 | 279.67B | 54.66B | 13.58B | 16.05B | 7.0171 |
Bristol Myers Squibb Co Stock (BMY) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-02-25 | Iniziato | RBC Capital Mkts | Sector Perform |
| 2026-02-20 | Iniziato | Barclays | Overweight |
| 2026-01-07 | Aggiornamento | UBS | Neutral → Buy |
| 2025-12-15 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2025-12-12 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2025-11-13 | Iniziato | Scotiabank | Sector Perform |
| 2025-08-05 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2025-04-22 | Iniziato | Cantor Fitzgerald | Neutral |
| 2025-04-22 | Iniziato | Piper Sandler | Overweight |
| 2024-12-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2024-12-10 | Ripresa | BofA Securities | Neutral |
| 2024-11-15 | Iniziato | Wolfe Research | Peer Perform |
| 2024-11-13 | Aggiornamento | Daiwa Securities | Neutral → Outperform |
| 2024-11-12 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-25 | Downgrade | Citigroup | Buy → Neutral |
| 2024-10-17 | Iniziato | Bernstein | Mkt Perform |
| 2024-07-29 | Downgrade | Barclays | Overweight → Equal Weight |
| 2024-03-11 | Downgrade | Societe Generale | Buy → Hold |
| 2024-02-06 | Downgrade | Redburn Atlantic | Buy → Neutral |
| 2024-01-03 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-11-15 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-11-02 | Downgrade | Daiwa Securities | Outperform → Neutral |
| 2023-10-27 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-10-27 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2023-10-27 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2023-10-20 | Ripresa | UBS | Neutral |
| 2023-07-14 | Iniziato | HSBC Securities | Reduce |
| 2023-07-10 | Iniziato | SVB Securities | Market Perform |
| 2023-06-28 | Iniziato | Daiwa Securities | Outperform |
| 2023-03-06 | Iniziato | Jefferies | Hold |
| 2023-01-17 | Iniziato | Cantor Fitzgerald | Overweight |
| 2022-11-18 | Iniziato | Credit Suisse | Neutral |
| 2022-10-10 | Downgrade | Guggenheim | Buy → Neutral |
| 2022-09-14 | Downgrade | Berenberg | Buy → Hold |
| 2022-06-03 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2022-04-06 | Ripresa | Morgan Stanley | Underweight |
| 2021-12-17 | Iniziato | Goldman | Buy |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-11-19 | Iniziato | BMO Capital Markets | Outperform |
| 2021-11-01 | Downgrade | Argus | Buy → Hold |
| 2021-07-27 | Ripresa | Truist | Buy |
| 2021-04-30 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-04-13 | Aggiornamento | Truist | Hold → Buy |
| 2020-11-16 | Aggiornamento | Societe Generale | Hold → Buy |
| 2020-11-10 | Ripresa | Bernstein | Mkt Perform |
| 2020-11-06 | Downgrade | Gabelli & Co | Buy → Hold |
| 2020-10-19 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-09-29 | Iniziato | Berenberg | Buy |
| 2020-07-28 | Iniziato | Raymond James | Outperform |
| 2020-04-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-03-23 | Downgrade | Societe Generale | Buy → Hold |
| 2020-02-27 | Iniziato | Barclays | Equal Weight |
| 2020-01-06 | Ripresa | Citigroup | Buy |
| 2019-12-13 | Aggiornamento | Argus | Hold → Buy |
| 2019-11-22 | Ripresa | Morgan Stanley | Equal-Weight |
| 2019-10-17 | Ripresa | BofA/Merrill | Buy |
| 2019-08-14 | Aggiornamento | Atlantic Equities | Neutral → Overweight |
| 2019-05-28 | Iniziato | Goldman | Buy |
| 2019-05-20 | Downgrade | Argus | Buy → Hold |
| 2019-05-03 | Aggiornamento | Barclays | Equal Weight → Overweight |
| 2019-05-03 | Ripresa | JP Morgan | Overweight |
| 2019-01-15 | Aggiornamento | Societe Generale | Sell → Buy |
| 2018-10-22 | Downgrade | Citigroup | Buy → Neutral |
Mostra tutto
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Bristol Myers Squibb: The CAR-T Giant The Market Is Undervaluing (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb Co. stock underperforms Friday when compared to competitors - MarketWatch
Bristol-Myers Squibb Co Stock (BMY) Moved Down by 3.18% on May 1: Drivers Behind the Movement - TradingKey
Bristol-Myers Loses Venue Fight to Texas in Plavix Litigation - Bloomberg Law News
Big Pharma M&A set for mega year as patent expiries drive deal urgency - Reuters
Bristol-Myers Squibb Company (NYSE:BMY) Q1 2026 Earnings Call Transcript - Insider Monkey
Bristol Myers’ legacy lift, Biogen’s blue skies and Regeneron’s murky outlook - Yahoo Finance
Bristol-Myers Squibb Co (BMY) Q1 2026 Earnings Call Highlights: - GuruFocus
Is Bristol Myers Squibb (BMY) Still Attractively Priced After Its Strong 1 Year Share Price Gain - simplywall.st
BMS brings the buzz around late-stage readouts amid a so-so Q1 - Pharmaceutical Technology
BMO raises Bristol-Myers Squibb stock price target on Eliquis beat - Investing.com Canada
SIIT U.S. Managed Volatility Fund's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb (NYSE:BMY) Posts Quarterly Earnings Results, Beats Expectations By $0.12 EPS - MarketBeat
Is Bristol-Myers Squibb Co (BMY) Overvalued After 5.2% Rally? GF - GuruFocus
Bristol-Myers Squibb (BMY) Reports Solid Q1 2026 Results with Po - GuruFocus
Bristol Myers Squibb Co. stock outperforms competitors on strong trading day - MarketWatch
Why Bristol Myers Squibb Stock Rocked the Market Today - The Motley Fool
Why Is Bristol-Myers Squibb Stock Trading Higher On Thursday? - Benzinga
Bristol Myers (BMY) Q1 2026 Earnings Transcript - The Motley Fool
MSN Money - MSN
INTECH INVESTMENT MANAGEMENT LLC's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers beats quarterly profit estimates on blood thinner, cancer drug sales - Reuters
Bristol Myers Squibb Surpasses Profit Expectations: Eliquis and Cancer Medicines Drive Growth - Devdiscourse
PUTNAM GLOBAL HEALTH CARE FUND's Bristol-Myers Squibb Co(BMY) Holding History - GuruFocus
Bristol Myers Squibb jumps after Q1 results and reaffirmed 2026 outlook - Quiver Quantitative
Bristol Myers Q1 2026 slides: growth portfolio drives revenue beat - Investing.com
Bristol Myers Squibb Company $BMY Shares Sold by Verity Asset Management Inc. - MarketBeat
Crohn’s Disease Market: Accelerating Growth and Pipeline Impact by 2034 – DelveInsight | Merck, Eli Lilly and Company, RedHill Biopharma, Bristol Myers Squibb, Dr. Falk Pharma GmbH, Janssen-Cilag Ltd - Barchart.com
Bristol Myers (BMY) Reports Q1 Earnings: What Key Metrics Have to Say - Yahoo Finance UK
Bristol Myers posts higher-than-expected quarterly profit on blood thinner, cancer sales - WNWN-FM
Bristol-Myers Squibb (BMY) Reports Strong Q1 2026 Earnings, Beats Expectations - GuruFocus
BMS beats estimates and reaffirms guidance - The Pharma Letter
Bristol Myers Squibb (BMY) Tops Q1 Earnings and Revenue Estimates - Yahoo Finance UK
Bristol Myers Squibb (NYSE:BMY) Q1 2026 Earnings Beat Driven by Growth Portfolio - ChartMill
Krazati's colorectal cancer approval in jeopardy | ApexOncoClinical Trials news and analysis - Oncology Pipeline
Bristol Myers Squibb (BMY) Q1 2026: EPS $1.31 Beats $1.19 Est., - GuruFocus
Bristol-Myers Squibb Company Stock (US0897961004): Q1 Revenues Rise 3% to $11.5 Billion - AD HOC NEWS
BRISTOL-MYERS SQUIBB ($BMY) Releases Q1 2026 Earnings - Quiver Quantitative
EDGAR Filing Documents for 0000014272-26-000008 - SEC.gov
Bristol-Myers Squibb trumps Q1 estimates, maintains full-year outlook By Investing.com - Investing.com India
Bristol Myers: Q1 Earnings Snapshot - KTVB
Bristol Myers Squibb (NYSE: BMY) posts Q1 2026 results, reaffirms 2026 guidance - Stock Titan
Bristol Myers Squibb Reports First Quarter Financial Results for 2026 - The Joplin Globe
Bristol Tops Estimates on New Drugs Ahead of Key Trial Results - Bloomberg.com
Bristol Myers Squibb Co. stock underperforms Wednesday when compared to competitors - MarketWatch
Bristol Myers Squibb Co. stock underperforms Tuesday when compared to competitors - MSN
Bristol-Myers earnings ahead: Can new drugs offset legacy slide? By Investing.com - Investing.com Nigeria
Bristol-Myers Squibb (BMY) Set for Earnings Decline Amid Positiv - GuruFocus
Fagan Associates Inc. Trims Stock Position in Bristol Myers Squibb Company $BMY - MarketBeat
Does Expanded MTAP-CDx Partnership With Foundation Medicine Change The Bull Case For Bristol-Myers Squibb (BMY)? - simplywall.st
Bristol Myers, Medtronic, Gilead: Top Dividend Healthcare Stocks in April 2026News and Statistics - IndexBox
Bristol Myers Squibb Co Azioni (BMY) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
1.39%
0.62%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):